China's top court applies safe harbor, rejects hub-and-spoke claims in drug dispute
China's top court has applied antitrust safe-harbor rules to resale-price restrictions in pharmaceutical distribution agreements, while rejecting allegations that a drugmaker organized a hub-and-spoke cartel among its distributors. The ruling illustrates the...To view the full article, register now.
Already a subscriber? Click here to view full article